Amicus Therapeutics Inc (FOLD)
10.41
+0.07
(+0.68%)
USD |
NASDAQ |
May 07, 16:00
10.42
+0.02
(+0.14%)
After-Hours: 20:00
Amicus Therapeutics Enterprise Value: 3.177B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 3.177B |
| May 06, 2024 | 3.156B |
| May 03, 2024 | 3.174B |
| May 02, 2024 | 3.182B |
| May 01, 2024 | 3.182B |
| April 30, 2024 | 3.053B |
| April 29, 2024 | 3.129B |
| April 26, 2024 | 3.138B |
| April 25, 2024 | 3.106B |
| April 24, 2024 | 3.215B |
| April 23, 2024 | 3.265B |
| April 22, 2024 | 3.298B |
| April 19, 2024 | 3.236B |
| April 18, 2024 | 3.153B |
| April 17, 2024 | 3.218B |
| April 16, 2024 | 3.221B |
| April 15, 2024 | 3.250B |
| April 12, 2024 | 3.256B |
| April 11, 2024 | 3.416B |
| April 10, 2024 | 3.431B |
| April 09, 2024 | 3.572B |
| April 08, 2024 | 3.528B |
| April 05, 2024 | 3.564B |
| April 04, 2024 | 3.487B |
| April 03, 2024 | 3.460B |
| Date | Value |
|---|---|
| April 02, 2024 | 3.460B |
| April 01, 2024 | 3.572B |
| March 28, 2024 | 3.581B |
| March 27, 2024 | 3.605B |
| March 26, 2024 | 3.478B |
| March 25, 2024 | 3.510B |
| March 22, 2024 | 3.507B |
| March 21, 2024 | 3.555B |
| March 20, 2024 | 3.646B |
| March 19, 2024 | 3.599B |
| March 18, 2024 | 3.522B |
| March 15, 2024 | 3.493B |
| March 14, 2024 | 3.510B |
| March 13, 2024 | 3.590B |
| March 12, 2024 | 3.584B |
| March 11, 2024 | 3.685B |
| March 08, 2024 | 3.735B |
| March 07, 2024 | 3.732B |
| March 06, 2024 | 3.823B |
| March 05, 2024 | 4.045B |
| March 04, 2024 | 4.078B |
| March 01, 2024 | 4.027B |
| February 29, 2024 | 3.888B |
| February 28, 2024 | 3.927B |
| February 27, 2024 | 4.193B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.402B
Minimum
Mar 12 2020
6.366B
Maximum
Dec 22 2020
3.135B
Average
3.060B
Median
May 18 2020
Enterprise Value Benchmarks
| TG Therapeutics Inc | 2.444B |
| Geron Corp | 1.929B |
| Vanda Pharmaceuticals Inc | -73.53M |
| Fate Therapeutics Inc | 69.87M |
| Editas Medicine Inc | 141.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.84M |
| Revenue (Quarterly) | 115.08M |
| Total Expenses (Quarterly) | 118.77M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 90.16% |
| Profit Margin (Quarterly) | -29.41% |
| Earnings Yield | -4.90% |
| Normalized Earnings Yield | -4.445 |